Zacks Investment Research Upgrades Clinigen Group (OTCMKTS:CLIGF) to Hold

Share on StockTwits

Clinigen Group (OTCMKTS:CLIGF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of OTCMKTS:CLIGF traded down $0.53 during trading hours on Wednesday, hitting $10.17. 5,250 shares of the company’s stock traded hands, compared to its average volume of 266. The firm has a market capitalization of $1.24 billion, a P/E ratio of 14.74 and a beta of -0.38. Clinigen Group has a 1 year low of $10.17 and a 1 year high of $10.70. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.95 and a quick ratio of 0.80. The business has a fifty day moving average price of $10.98 and a 200-day moving average price of $12.30.

See Also: What is channel trading?

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Morgan Stanley Boosts AMETEK  Price Target to $109.00
Morgan Stanley Boosts AMETEK Price Target to $109.00
Amneal Pharmaceuticals  Upgraded at ValuEngine
Amneal Pharmaceuticals Upgraded at ValuEngine
Antero Resources’  Hold Rating Reaffirmed at Evercore ISI
Antero Resources’ Hold Rating Reaffirmed at Evercore ISI
ASGN  Stock Rating Lowered by Zacks Investment Research
ASGN Stock Rating Lowered by Zacks Investment Research
Yamana Gold  Receives “Sell” Rating from Barclays
Yamana Gold Receives “Sell” Rating from Barclays
American Water Works  Price Target Increased to $129.00 by Analysts at JPMorgan Chase & Co.
American Water Works Price Target Increased to $129.00 by Analysts at JPMorgan Chase & Co.


© 2006-2019 Ticker Report